Introduction
Peripheral arterial disease (PAD) is a manifestation of systemic atherosclerosis that affects approximately 8-12 million Americans and is associated with significant cardiovascular (CV) morbidity and mortality. 1, 2 Recently, the PAD Awareness, Risk and Treatment (PARTNERS) study reported that PAD was underrecognized and that only 60% were receiving lipid lowering therapy. 3 This is alarming given the current Adult Treatment Prevention (ATP) III Guidelines that defines PAD as a high risk category requiring intensive lipid management. 4 The PARTNERS study also found that other risk factors for atherosclerosis including hypertension and diabetes were undertreated, and antiplatelet therapy was underutilized compared to patients with diagnosed cardiovascular disease (CVD). Therefore, although PAD patients would benefit from aggressive risk factor management, they typically receive less intensive treatment than CVD patients. Lack of reimbursement for PAD screening, and inadequate implementation of current practice guidelines may be barriers to effective treatment of risk factors in PAD. 3, 5, 6 The purpose of this study was to determine if dissemination of practice guidelines for patients with cardiovascular disease, and publication of the seminal paper describing the results of the PARTNERS study, had affected current management of PAD in the community.
Risk factor profile
Risk factor profile and treatment was determined by self-reported medical history and current medications. All medications were verified by visual inspection of medication bottles during the clinic visit. Measurement of resting BP, serum clinical chemistries and lipids were used to confirm self-report, to detect new or untreated cases and to evaluate the severity of the risk factor in recognized cases.
Risk factor profile was characterized as: (1) recognized (self-reported medical history) with optimal management if therapy was instituted (medication record), and objective measurement of the risk factor that met the currently recommended treatment guidelines as defined below; (2) recognized with suboptimal management if treatment was instituted, but objective measurement of the risk factor did not meet the currently recommended treatment guidelines as defined below; and (3) unrecognized if objective measurement revealed a value for the risk factor that did not meet the currently recommended treatment guidelines, and the risk factor was not recognized as determined by a review of the medical history not reported by the patient and current medication records.
The current study utilized current treatment guidelines for lipids, hypertension and diabetes. Dyslipidemia was defined by the ATP III guidelines as LDL-cholesterol Ն100 mg/dl. Hypertension was defined by the Joint National Committee (JNC) VI guidelines and included SBP Ն140 mmHg, and diastolic blood pressure (DBP) Ն90 mmHg. Hemoglobin A1c (HgbAlc) level Ն7% indicated suboptimal glycemic control.
Statistical analysis
Demographic and clinical characteristics of the study sample are reported as means and standard deviations. Independent sample Student's t-tests procedures were used to evaluate between group differences. Medical history information was analyzed using 2 tests with Fischer exact test statistics. The ␣ level was set at 0.05 using a two-tailed test of significance.
Results

Dyslipidemia
The study sample consisted of 101 subjects. Sample demographics and clinical characteristics are shown in Tables 1 and 2. Dyslipidemia was recognized in 56.4% (n ϭ 57) of subjects (Table 3) . Suboptimal therapy was observed in 52.6% (n ϭ 30) of dyslipidemic subjects, with LDL-C Ͼ100 mg/dl. Additionally, 20.8% (n ϭ 21) of the total sample were newly identified as dyslipidemic (unrecognized cases).
Of subjects with dyslipidemia, 68% were prescribed at least one lipid lowering agent. HMG CoA reductase inhibitors (statins) were most commonly prescribed (64%), while 13% were on other cholesterol-lowering agents. Individuals prescribed statins had significantly lower total cholesterol (TC) and LDL levels than those not on statins (p Ͻ 0.001)
Hypertension
History of hypertension was reported in 54.5% (n ϭ 55) of the study sample. Of hypertensives, mean SBP was 151 Ϯ 18 mmHg, range ϭ 108-191 mmHg, DBP was 72 Ϯ 9 mmHg, range 50-91.
Management of SBP was suboptimal in 74.5% (n ϭ 41) of hypertensive subjects. Systolic hypertension was unrecognized in 13.9% (n ϭ 14) of the sample with a mean SBP of 156 Ϯ 13 mmHg (range ϭ 140-178).
Of hypertensives, 81% were taking at least one type of antihypertensive medication. Triple therapy (39.1%, n ϭ 27) was the most common treatment regimen, followed by monotherapy 14.5% (n ϭ 10) and dual therapy in 30.4% (n ϭ 21). Combinations of four 10.1% (n ϭ 7) or more 1.4% (n ϭ 1) antihypertensive medications were less commonly prescribed. In hypertensives, those patients on diuretics alone, had similar BP as those on triple therapy. SBP on monotherapy was 150 Ϯ 17.6 mmHg, range ϭ 108-191, and DBP ϭ 71 Ϯ 9 mmHg, range ϭ 50-92 mmHg. SBP on triple therapy was 151 mmHg Ϯ 18 (range ϭ 108-182) and DBP was 70 Ϯ 7 mmHg (range ϭ 57-84).
Diabetes
History of diabetes was reported in 26.7% (n ϭ 27) of the study sample. The mean fasting blood glucose for diabetics was 160 Ϯ 79 mg/dl (range ϭ 40-368). Hemoglobin A1c was 7.9 Ϯ 1.9 mg/dl (range ϭ 5.9-14.70). Suboptimal glycemic control was found in 57% of diabetics (mean HgbA1c ϭ 8.7 Ϯ 1.8, range ϭ 7-14.70). In those with optimal glycemic control the mean HgbA1c was 6.3 Ϯ 0.45 mg/dl (range ϭ 5.6-6.9; n ϭ 9).
Medications for diabetics included sulfonylureas (37%), biguanides (13%), insulin (17%), and other types of medications (37%). Notably, only 5% of diabetics adhered to the ADA diet. In diabetics, dyslipidemia and hypertension were not optimally controlled. However, no difference was noted in intensity of risk factor management between diabetics and nondiabetics.
Approximately 25% of the total sample (n ϭ 25) reported a combination of hypertension and diabetes. Of those diabetics with hypertension, 12% (n ϭ 3) reported use of one antihypertensive agent, 24% (n ϭ 6) two agents, 48% (n ϭ 12) three agents, 8% (n ϭ 2) four and 4% (n ϭ 1) five antihypertensive medications. Despite treatment with antihypertensive drugs, the mean SBP of the group remained elevated (mean ϭ 151 Ϯ 17, range ϭ 108-182 mmHg.). Of note, all subjects with diabetes and hypertension reported current treatment with statins.
Anticoagulation/antiplatelet therapy
Of the entire study population, 62% were using antiplatelet therapy and anticoagulation therapy was employed in only 15% of patients. Aspirin use was the most common antiplatelet therapy (57%), followed by clopidogrel (10%), and a variety of other medications (7%). Approximately 35% of subjects (n ϭ 36) were not currently taking either anticoagulant or antiplatelet therapy; in this untreated group, none had an apparent contraindication to antiplatelet therapy.
Other risk factors
In this sample, 68% were ex-smokers, averaging 20 (Ϯ15) years smoke free. Of the 8 current smokers, only one was receiving pharmacologic tobacco cessation therapy. Participation in physical activity was reported by 54% of the sample. Exercise consisted of walking (40%), for 37 Ϯ 20 minutes, 4.2 Ϯ 1.7 days weekly. Only 36% of subjects reported following prescribed dietary guidelines for a low fat (48%) or a (31%) low sodium diet. Regular use of dietary supplements was reported by 56% of the sample, most commonly, antioxidants Vitamin E and C. The mean BMI for the study sample was 27.4 Ϯ 4.8, with 39% overweight, and 28% obese.
Discussion
The salient finding of this study is that in PAD patients, risk factors are undertreated. Despite JNC VI and ATP III guidelines, the current study found that the majority of subjects with recognized risk factors i.e. patients with dyslipidemia (53%), hypertension (74%) and diabetes (67%) were not optimally treated. Additionally, 38% of subjects were not receiving antiplatelet therapy. Notably, there were a number of PAD patients with unrecognized risk factors particularly dyslipidemia (21%) and hypertension (14%). This small observational descriptive study extends the results of the PARTNERS study and others, that reported suboptimal management of PAD patients. 3, 6 The current study demonstrates that two years after the publication of the PARTNERS study and despite established practice guidelines for CVD risk factors including diabetes and hypertension, risk factors are not intensively treated in PAD.
Dyslipidemia
The NCEP calls for aggressive lipid lowering in PAD patients. 4 Although there have been conflicting data on the magnitude of the individual roles of HDL, LDL, and TC in PAD 7-9 there appears to be a positive correlation between cholesterol levels and PAD. 10 In the current study, a majority (56%) of PAD patients were dyslipidemic, an additional 21% of the total sample were unrecognized at entry into the trial. If dyslipidemia was recognized, only 47% achieved ATP III treatment goals for LDL-C levels. The rate of treatment to guideline goals in the current trial was lower than that observed in the PARTNERS study. These results may reflect a lack of patient awareness, a lack of detection of dyslipidemia, and/or lack of awareness or application of treatment guidelines. 6
Hypertension
The prevalence of hypertension among PAD patients detected in this trial was lower than the Framingham Offspring Study (69%) and the PARTNERS study (88%) of PAD patients. 3 These results may reflect differences in the study populations and methods to assess PAD. Of more importance to the current investigation is that 74% of patients with recognized hypertension received suboptimal treatment. Moreover, almost 14% of the entire sample had unrecognized hypertension. Current guidelines for the detection and treatment of hypertension considers PAD as clinical evidence of CVD necessitating intensive pharmacologic management. 10 Therefore, all PAD patients with hypertension should receive aggressive management. 11 Approximately 80% of patients were on at least one type of antihypertensive medication.
The results from this small observational descriptive study illustrate the challenges faced by practitioners for effective BP management as the majority of cases have been recognized and treatment has been extended. However, we find that in the majority of patients there is inadequate BP control. This may be due to poor compliance, inadequate monitoring of drug effect, suboptimal dosing or lack of attention to adjunctive non-pharmacological measures such as diet and exercise. As stated earlier, dosing and subject adherence were not assessed in this study.
Diabetes
Diabetes is an extremely important determinant of the severity of atherosclerotic disease. 12, 13 Studies show that diabetic PAD patients have poorer leg function, higher BMI, increased neuropathy and an increased number of cardiovascular comorbidities than those with PAD alone. [13] [14] [15] [16] [17] These complications are associated with increased risk of gangrene and ulcerations and higher incidence of amputation. 18 Additionally, inadequate treatment of diabetes increases the risk of mortality in PAD patients. 19 Therefore, detection and treatment of diabetes in PAD patients is imperative.
Consistent with the PARTNERS study, in our study a majority of diabetics (85%) reported taking at least one type of antidiabetic medication. 3 Nonetheless, HgbA1c was higher than the recommended range for more than half of the diabetics suggesting inadequate glucose control. Only 2% of the study sample had unrecognized diabetes indicating adequate detection. In contrast to other risk factors, there was a high degree of concordance between medications prescribed and self-reported diabetes confirming adequate awareness and knowledge of the diagnosis.
In addition to pharmacologic treatment, dietary interventions effectively reduce the dosage of insulin needed for adequate glucose control. 20 Remarkably, only 5% of the study sample reported adhering to an ADA diet. These results suggest that despite better pharmacological management of diabetes (by comparison to other risk factors), nonpharmacologic interventions are seriously underutilized in diabetic patients with PAD.
Anticoagulant/antiplatelet therapy
Antiplatelet treatment, with aspirin 75-325 mg/day, confers longevity in individuals with cardiovascular disease. 16, 21 Despite the beneficial effects of antiplatelet therapy, nearly half of the study sample was not using aspirin. 6 Only 10% of patients were prescribed clopidogrel, which has greater efficacy than aspirin in reducing cardiovascular events in PAD patients. 22, 23 The available evidence suggests that all PAD patients should be on antiplatelet therapy unless there is a compelling contraindication. 3, 5, 23 Smoking Tobacco exposure is a powerful predictor of PAD and has been linked to progression of symptoms and increased mortality. 18, 24, 25 Consequently, smoking needs to be aggressively eliminated from the lifestyle of these patients.
With respect to the prevalence of smoking in the PAD population, the results from this study are dissimilar to those of the PARTNERS study and the Rotterdam study which reported that almost 70% of the PAD patients were active smokers. 24 In the current study, less than a tenth of the study sample were current smokers. The low rate of current smokers may reflect the aggressive political and social anti-smoking measures that have been instituted in California.
Of those current smokers, only one reported active use of any tobacco cessation treatment. As cigarette smoking is a disease of nicotine dependence, passive recommendations are generally not sufficient to permanently curb smoking habits. A meta-analysis of controlled trials of nicotine-replacement therapy (NRT) revealed that NRT increased the odds ratio of permanent tobacco cessation and its efficacy was largely independent of the intensity and setting of additional support. 13, [26] [27] [28] Therefore, all active smokers should be offered nicotine replacement therapies and other pharmacologic measures to curb tobacco dependency.
A limitation of this study was the use of selfreported smoking history without validation by biological markers. In addition, degree of tobacco use by determination of pack years could have been informative. However, for the purposes of this study, point prevalence and history of regularity in smoking habits was sufficient to evaluate the extent of the risk and the intensity of the treatment in the study population.
Lifestyle modification
Nonpharmacologic interventions such as diet and exercise are effective in reducing CV events. [29] [30] [31] In addition, participation in a regular program of exercise has been demonstrated to improve claudication and increase walking distance. 32, 33 Despite the demonstrated efficacy of exercise in PAD patients, almost half of the study sample was sedentary. Although the current study did not explore the barriers to physical activity, a number of factors may have influenced this result including lack of adherence or lack of health education and perhaps most importantly lack of funding from third party payors for vascular rehabilitation programs.
Weight management may confer additional benefits by increasing walking distance, and by reducing the exposure to other risk factors. 34 Weight as measured by BMI was positively associated with PAD in an age and sex-adjusted analysis. 25 Approximately one third of the current study sample was overweight and nearly a third was obese by ATP-III guidelines. However, only 31% of subjects were taking dietary measures to improve their cardiovascular health, and even fewer were physically active. These results suggest that routine follow-up of dietary and exercise guidelines and monitoring of body weight need implementation in this patient population.
Limitations
The primary limitation to the current study is the small sample size that may contribute to a type II statistical error, thus differences between groups may not have been detected. Despite the small sample size, the results from this study are similar to those of the larger national PARTNERS study that showed the lack of detection and treatment of CVD risk factors in PAD patients. Change in treatment intensity is typically detectable only after promulgation of care guidelines by national societies and healthcare systems, combined with intensive efforts towards physician education. Accordingly, our findings reflect the lack of a major national effort to improve care in the PAD population.
Conclusion
This study confirms and extends the results of earlier trials that found that cardiovascular risk factors are underdetected and undertreated in PAD patients. Recognition and treatment of hyperlipidemia and hypertension in PAD patients is suboptimal and would greatly benefit from more aggressive detection and management. Diabetes in PAD patients appears to be detected more reliably although glycemic control is still suboptimal. In many hypertensive patients treatment is not optimal. The use of antiplatelet therapy is particularly underutilized. To rectify suboptimal management of risk factors, there is a need for increased public awareness of PAD, reimbursement and implementation of screening programs, more aggressive treatment and development of national PAD management guidelines. Innovative high throughput methods for identification of patients with peripheral arterial disease would substantially enhance recognition and treatment of this common, but commonly unrecognized and undertreated disease.
